Merck & Co. Inc. may have settled the bulk of its Vioxx cases, but it plans to try each of the 2,950 New Jersey suits that fall outside the agreement.

The company’s $4.85 billion settlement, which is still subject to approval by 85 percent of qualifying claimants, would cover 10,050 plaintiffs in New Jersey and another 13,600 nationwide who can prove they suffered a heart attack or ischemic stroke within 14 days of taking the drug.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]